Therapeutic approach to lung disease

Patent metadata

Field	Value
Publication number	US-12521389-B2
Application number	US-202017618700-A
Country	US
Kind code	B2
Filing date	Jun 12, 2020
Priority date	Jun 14, 2019
Publication date	Jan 13, 2026
Grant date	Jan 13, 2026

Abstract

The present disclosure provides a novel animal model of NEHI, and method of preventing and/or treating a pulmonary disease, particularly the lung-based complications in NEHI, such as pulmonary edema, by targeting the PNEC product, such as the CGRP signaling. Also disclosed is the pharmaceutical composition for preventing and/or treating a pulmonary edema and/or other pulmonary disease, particularly, NEHI, comprising one or more CGRP signaling antagonist and/or inhibitor of the present disclosure.

First claim

What is claimed is:

1 . A method of treating a pulmonary edema in a patient comprising administering to the patient a therapeutically effective amount of a CGRP signaling antagonist selected from the group consisting of olcegepant (BIBN4096BS), telcagepant (MK-0974), rimegepant (BMS-927711), BI 44370 TA, MK-3207, ubrogepant (MK-1602), and MK-8031.

2 . The method of claim 1 , wherein the pulmonary edema is NEHI.

3 . The method of claim 1 , wherein said method further comprises administering supplemental oxygen.

4 . A pharmaceutical composition for treating a pulmonary edema in a patient in need thereof, comprising a therapeutically effective amount of one or more CGRP signaling antagonists selected from the group consisting of olcegepant (BIBN4096BS), telcagepant (MK-0974), rimegepant (BMS-927711), BI 44370 TA, MK-3207, ubrogepant (MK-1602), and MK-8031.

5 . The pharmaceutical composition of claim 4 , wherein the CGRP signaling antagonist is formulated in a pharmaceutically acceptable carrier or excipients for a proper administration.

6 . The pharmaceutical composition of claim 5 , wherein the CGRP signaling antagonist is administered via inhalation to the lung of the patient.

7 . The pharmaceutical composition of claim 6 , wherein administration of the CGRP signaling antagonist via inhalation is accomplished using a dry powder inhaler, a pressurized metered dose inhaler, or a nebulizer.

8 . The pharmaceutical composition of claim 4 , wherein the pulmonary edema is NEHI.

9 . The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition further comprises supplemental oxygen.

10 . The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is administered with supplemental oxygen.

Assignees

• Univ California
• Childrens Hospital Of Philadelphia
• Young Lisa R
• Univ Vanderbilt
• Childrens Hospital Philadelphia

Inventors

• Sun Xin
• Xu Jinhao
• Young Lisa

Classifications

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K9/1617

  Organic compounds, e.g. phospholipids, fats · CPC title

• A61K9/0075

  for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K33/00

  Medicinal preparations containing inorganic active ingredients · CPC title